Gunderson Dettmer represented client Lightspeed Venture Partners as it led the $101 million Series A financing of Seismic Therapeutic, a biotechnology company advancing machine learning for immunology drug development. Seismic’s new funding will support its first two lead drug programs, targeting Ig-mediated autoimmunity and cell-mediated autoimmunity, and will enable the company to continue the development of its propriety IMPACT platform to make advancements to machine learning technologies applied to immunology therapeutics.

In the announcement of the transaction, Partner at Lightspeed Venture Partners, Shelley Chu, MD, PhD said, “The Seismic team has made rapid progress in building a world-class platform for immunology drug innovation, incorporating the power of machine learning and guided by the team’s expert drug hunters, technology integrators and company builders. We look forward to the exciting future for this company and the immunology medicines it will advance for patients.”

The Gunderson deal team was co-led by Marcia Hatch and Nate Gray and included Jake Plotnik, Gina Marek, Alice Lu and Joel Diamond.

Companies:
Lightspeed Venture Partners
Seismic Therapeutic